CSIMarket
 

Crispr Therapeutics Ag  (CRSP)
Other Ticker:  
 

Crispr Therapeutics Ag's

Competitiveness


 

CRSP Sales vs. its Competitors Q3 2023







Revenue Growth Comparisons




Net Income Comparison




<<  CRSP Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Crispr Therapeutics Ag Contracts

Transforming Beta Thalassemia Treatment: FDA Approval of CASGEVY, a One-time CRISPR Therapeutics Solution Transforms Patient Prospects

The field of gene editing and therapeutic techniques has recently witnessed a monumental stride as the FDA (U.S. Food and Drug Administration) sanctions a pioneer gene-editing treatment for Transfusion-Dependent Beta Thalassemia (TDT). The approach, CASGEVY (exagamglogene autotemcel), manufactured by CRISPR Therapeutics, manifests an innovative potential for gene-editing technology in the pharmaceutical scene.Beta Thalassemia is a perilously severe genetic blood disorder characterized by chronic anemia, fatigue, and an excess of iron in the blood, resulting from the inadequate production of hemoglobin. For TDT patients, frequent blood transfusions become a distressing norm of life. CASGEVY advances a unique ...





Who are Crispr Therapeutics Ag's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com